Iovance Biotherapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Iovance Biotherapeutics

06/05/2025 22:30

Iovance Biotherapeutics Inc IOVA.OQ IOVA.O is expected to show a rise in quarterly revenue when it reports  results on May 8 for the period ending March 31 2025

The San Carlos California-based  company is expected to report a 11,327.2% increase in revenue to $81.705 million from $715 thousand a year ago, according to the mean estimate from 11 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Iovance Biotherapeutics Inc is for a loss of 24 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 0.3% in the last three months. ​

Wall Street's median 12-month price target for Iovance Biotherapeutics Inc is $18.00​, above​ its last closing price of $3.50. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.27
-0.27
-0.26
Beat
2.7
Sep. 30 2024
-0.31
-0.30
-0.28
Beat
6.4
Jun. 30 2024
-0.35
-0.35
-0.34
Beat
3.8​
Mar. 31 2024
-0.42
-0.42
-0.42
Met
0.6
​​Dec. 31 2023
-0.43
-0.43
-0.45
Missed
-4.3
Sep. 30 2023
-0.46
-0.45
-0.46
Missed
-1.3​
Jun. 30 2023
-0.82
-0.80
-0.47
Beat
41
Mar. 31 2023
-0.77
-0.74
-0.50
Beat
32.9

This summary was machine generated May 6 at 21:30 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)